Insider Buying: Opko Health Inc. (OPK) CEO Buys 100,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost bought 100,000 shares of the stock in a transaction on Monday, January 22nd. The shares were acquired at an average cost of $4.40 per share, for a total transaction of $440,000.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at $13,503,384.40. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Opko Health Inc. (NASDAQ:OPK) opened at $4.44 on Tuesday. Opko Health Inc. has a 1-year low of $4.28 and a 1-year high of $8.92. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.48 and a current ratio of 1.66. The stock has a market capitalization of $2,480.00, a PE ratio of -23.37 and a beta of 1.82.

Opko Health (NASDAQ:OPK) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The company had revenue of $263.50 million during the quarter, compared to analyst estimates of $319.43 million. During the same quarter last year, the firm posted ($0.03) earnings per share. The firm’s revenue for the quarter was down 11.6% compared to the same quarter last year. sell-side analysts anticipate that Opko Health Inc. will post -0.27 earnings per share for the current year.

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald set a $20.00 price target on Opko Health and gave the company a “buy” rating in a report on Wednesday, October 25th. Zacks Investment Research upgraded Opko Health from a “sell” rating to a “hold” rating in a report on Thursday, October 26th. BidaskClub lowered Opko Health from a “hold” rating to a “sell” rating in a report on Saturday, November 11th. Finally, Ladenburg Thalmann Financial Services reiterated a “buy” rating and set a $16.00 price target on shares of Opko Health in a report on Monday, September 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the stock. Opko Health currently has an average rating of “Hold” and a consensus target price of $13.34.

A number of institutional investors and hedge funds have recently bought and sold shares of OPK. Schwab Charles Investment Management Inc. lifted its holdings in Opko Health by 20.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,095,177 shares of the biotechnology company’s stock worth $7,207,000 after purchasing an additional 189,438 shares during the last quarter. Legal & General Group Plc lifted its holdings in Opko Health by 7.9% in the 2nd quarter. Legal & General Group Plc now owns 120,518 shares of the biotechnology company’s stock worth $793,000 after purchasing an additional 8,845 shares during the last quarter. Prudential Financial Inc. lifted its holdings in Opko Health by 6.1% in the 2nd quarter. Prudential Financial Inc. now owns 24,511 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 1,400 shares during the last quarter. Swiss National Bank lifted its holdings in Opko Health by 2.3% in the 2nd quarter. Swiss National Bank now owns 562,100 shares of the biotechnology company’s stock worth $3,699,000 after purchasing an additional 12,900 shares during the last quarter. Finally, Alliancebernstein L.P. lifted its holdings in Opko Health by 18.6% in the 2nd quarter. Alliancebernstein L.P. now owns 213,324 shares of the biotechnology company’s stock worth $1,404,000 after purchasing an additional 33,400 shares during the last quarter. Hedge funds and other institutional investors own 22.88% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Insider Buying: Opko Health Inc. (OPK) CEO Buys 100,000 Shares of Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2018/01/23/insider-buying-opko-health-inc-opk-ceo-buys-100000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply